Titel
Accueil
Navigation principale
Contenu
Recherche
Aide
Fonte
Standard
Gras
Identifiant
Interrompre la session?
Une session sous le nom de
InternetUser
est en cours.
Souhaitez-vous vraiment vous déconnecter?
Interrompre la session?
Une session sous le nom de
InternetUser
est en cours.
Souhaitez-vous vraiment vous déconnecter?
Accueil
Plus de données
Partenaires
Aide
Mentions légales
D
F
E
La recherche est en cours.
Interrompre la recherche
Recherche de projets
Projet actuel
Projets récents
Graphiques
Identifiant
Titel
Titel
Unité de recherche
PCRD EU
Numéro de projet
01.0282
Titre du projet
FLUOR MMPI: Selective fluorinated inhibitors of matrix metalloproteinases 3 and 9
Titre du projet anglais
FLUOR MMPI: Selective fluorinated inhibitors of matrix metalloproteinases 3 and 9
Données de base
Textes
Participants
Titel
Textes relatifs à ce projet
Allemand
Français
Italien
Anglais
Mots-clé
-
-
-
Autre Numéro de projet
-
-
-
Programme de recherche
-
-
-
Description succincte
-
-
-
Autres indications
-
-
-
Résumé des résultats (Abstract)
-
-
-
Références bases de données
-
-
-
Textes saisis
Catégorie
Texte
Mots-clé
(Anglais)
Education; Training; Scientific Research; Social Aspects
Autre Numéro de projet
(Anglais)
EU project number: HPRN-CT-2002-00181
Programme de recherche
(Anglais)
EU-programme: 5. Frame Research Programme - 4.1.1 Research training networks
Description succincte
(Anglais)
See abstract
Autres indications
(Anglais)
Full name of research-institution/enterprise:
ETH Zürich
Institut für Pharmazeutische Wissenschaften
ETH Hönggerberg, HCI G 396.4
Résumé des résultats (Abstract)
(Anglais)
Heart failure and cancer are the two major causes of death in developed countries. Current therapies for their cure are affected by largely unsolved problems. A common feature of both pathologies is that matrix metalloproteinases (MMPs) 3 and 9, which are zinc-dependent proteolytic enzymes, play a key role. Inhibitionof MMPs 3 and 9 is promising for heart failure and cancer therapy, but the currently available inhibitors are poorly selective, and therefore toxic. The primary objective of this project is to discover novel families of inhibitors selective for MMPs 3 and 9 from fluorinated peptidomimetic units. This challenging goal will be pursued by exploiting the potent tools made available by a synergistic and multisciplinary collaboration encompassing all aspects of drug discovery, including fluorine/asymmetric/combinatorial chemistry, structural chemistry, modelling, protein crystallography, pharmacology, physiology and biology, with the additional support of an industrial partner. The other main objective of this research project is to provide an effective training for young scientists at the interface of chemistry and biology in a very competitive international context where discovery of new drugs rests mainly on the ability to use complementary approaches from various disciplines and expertises.
Eventually, the scientific achievements stemming from this project will improve our knowledge of a variety of timely and fundamental topics such as:
1) the asymmetric/combinatorial synthesis of chiral fluorinated peptides and mimetics;
2) the mechanism of action of MMPs;
3) the behaviour of fluorine-containing functions in the enzyme active sites, as well as of their influence on the recognition of the ligand by the enzymes and the effect on the binding affinity;
4) the in vivo tests of the fluorinated inhibitors, and;
5) the generation of human monoclonal antibodies against MMP-3 and MMP-9.
Références bases de données
(Anglais)
Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. +41 31 322 74 82
Swiss Project-Number: 01.0282
SEFRI
- Einsteinstrasse 2 - 3003 Berne -
Mentions légales